Assistance requested - Impact of the Prometheus and Myriad decisions of the US Supreme Court on your IP and licensing strategy

By Denise Hirsch posted 08-09-2016 05:46

  

Dear all,

 

I would like to request your assistance in helping us assessing the impact of the Prometheus and Myriad decisions of the US Supreme Court on your IP and licensing strategy with respect to the medical field , in particular diagnosis e.g. biomarkers.

The Questionaire for which we provide the following link  has been designed in order to collect the responses of the most relevant TTOs worldwide.

Please complete it wherever you feel comfortable in providing data and sharing your experience.

 

https://goo.gl/forms/3TyakNbrSUDAGcVe2

 

We hope to collect the response by the end of August.

 

All data will be anonymously processed  and the outcome of the questionnaire will be presented  by Denise Hirsch, head of The department “ Protection and Institutional partnerships “ of Inserm Transfert , the private subsidiary of Inserm in charge of IP management and Industrial Partnerships ,at the AIPPI congress of Milan  that will take place September 16-20 in the panel session entitled: “In(gene)ious but not patentable? Patentable subject matter”.

 

http://www.aippi2016.it/wp/programme/

 

The outcome will also be shared with the responders in advance of the Congress.

I thank you in advance for your kind assistance.

 

For any question, you may contact:

 

·         Sylvestre Chea: until August 19th

Sylvestre.chea@inserm-transfert.fr

Tel: +33 1 55 03 01 67

 

·         Pauline Solignac: from August 22nd

Pauline.solignac@inserm-transfert

Tel:+33 1 80 05 86 27

 

·         Denise Hirsch

Denise.hirsch@inserm-transfert.fr

Tel: +33 6 26 20 07 23 

0 comments
312 views

Permalink